---
title: "Vaxart files preliminary proxy, urges support for board as Phase 2b COVID readout, $61M cash runway into Q2 2027"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286969427.md"
description: "Vaxart has filed a preliminary proxy and urged shareholders to support its board as it progresses with a Phase 2b COVID-19 trial. The trial is fully enrolled with 5,400 participants, and results are expected in early 2027. The company reported a strong financial position with $61M cash, ensuring funding into Q2 2027. Actions taken to extend runway include restoring BARDA funding and a strategic partnership with Dynavax."
datetime: "2026-05-19T21:23:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286969427.md)
  - [en](https://longbridge.com/en/news/286969427.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286969427.md)
---

# Vaxart files preliminary proxy, urges support for board as Phase 2b COVID readout, $61M cash runway into Q2 2027

**Vaxart filed a preliminary proxy and issued an open letter urging shareholders to support its board as it advances a Phase 2b COVID-19 trial and other vaccine programs.**

**Key Highlights:**

-   Filed preliminary proxy and issued shareholder letter supporting six board nominees ahead of July 16, 2026 Annual Meeting.
-   Phase 2b COVID-19 trial fully enrolled (~5,400 participants); 12-month sentinel safety data expected Q2 2026; primary readout anticipated early 2027.
-   Highlights norovirus and influenza programs as potential first-in-class and differentiation opportunities; pursuing partnerships and funding.
-   Reports strengthened financial position: ~$61M cash at end of Q1 2026, funded runway into Q2 2027 and $25M share purchase agreement available.
-   Notes actions taken to extend runway: restored BARDA funding, strategic partnership financing with Dynavax, HQ relocation, and 21% workforce reduction.

Original SEC Filing: Vaxart, Inc. \[ VXRT \] - 8-K - May. 19, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [DVAX.US](https://longbridge.com/en/quote/DVAX.US.md)
- [VXRT.US](https://longbridge.com/en/quote/VXRT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

- [Vaxart Urges Shareholder Support Amid Proxy Contest, Updates Pipeline](https://longbridge.com/en/news/286974394.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)